 ASLAN Pharmaceuticals Ltd NASDAQ: ASLN has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis AD. In March 2021, ASLAN announced interim data from three dose-escalation cohorts 200mg, 400mg, and 600mg. 